The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 16 November 2004, www.theannals.com, DOI 10.1345/aph.1E269.
The Annals of Pharmacotherapy: Vol. 39, No. 1, pp. 22-27. DOI 10.1345/aph.1E269
© 2005 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow For Our Patients
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Patel, H. R
Right arrow Articles by Hall, L. E
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Patel, H. R
Right arrow Articles by Hall, L. E

NEPHROLOGY

Assessment for Chronic Kidney Disease Service in High-Risk Patients at Community Health Clinics

Harita R Patel, PharmD

Clinical Pharmacist, Shands Jacksonville, Jacksonville, FL

Maria C Pruchnicki, PharmD BCPS

Clinical Assistant Professor, College of Pharmacy, The Ohio State University, Columbus, OH

Laura E Hall, PharmD BCPS

Clinical Assistant Professor, College of Pharmacy, The Ohio State University

Reprints: Dr. Patel, Shands Jacksonville, 655 W. 8th St., Jacksonville, FL 32209-6511, fax 904/244-4998, Harita_patel{at}hotmail.com

BACKGROUND: Chronic kidney disease (CKD) poses significant public health concerns. Early identification and interventions can help prevent or slow progression to end-stage renal disease.

OBJECTIVE: To characterize CKD in high-risk indigent patients in a primary care setting and evaluate opportunities for pharmacists to work collaboratively with physicians to improve medication use and CKD patient outcomes.

METHODS: Medical records of 200 patients with diabetes mellitus and/or hypertension were reviewed by the clinical pharmacist. Estimated glomerular filtration rate (creatinine clearance [Clcr]) and urinalysis were used to identify and stage CKD according to published guidelines. Glycosylated hemoglobin concentrations and blood pressures were recorded. The pharmacist evaluated medications for possible drug-related problems (DRPs), made therapeutic recommendations, and evaluated the acceptance rate by physicians.

RESULTS: One hundred nineteen patients met inclusion criteria, and a total of 68.9% met CKD criteria: stage 1, 16.0%; stage 2, 20.2%; stage 3, 25.2%; stage 4, 1.7%; stage 5, 0.8%; and not stageable, 5.0%. A total of 381 DRPs were identified, averaging 3.2 (1.7) per patient (range 0-11). The number of DRPs correlated with Clcr (r = -0.25; p = 0.007). Therapeutic recommendations included change of drug, dose and/or interval adjustment of the current drug, discontinuation of nonsteroidal antiinflammatory drugs, additional laboratory monitoring, meeting goal blood pressure and glycosylated hemoglobin, adding renoprotective drug and/or low-dose aspirin, and nephrologist referral. Fewer than half (40.9%) of the recommendations were accepted or accepted with modifications, and an approximately equal percentage were not accepted by the physicians.

CONCLUSIONS: CKD prevalence was high among the patients evaluated here. New guidelines are available to assist in managing CKD ambulatory patients. Pharmacist collaboration with physicians may optimize CKD screening in high-risk patients and improve medication usage.

Key Words: ambulatory care, chronic kidney disease, National Kidney Foundation

Published Online, November 16, 2004. www.theannals.com, DOI 10.1345/aph.1E269


This article has been cited by other articles:


Home page
QJMHome page
G. Dreyer, S. Hull, Z. Aitken, A. Chesser, and M.M. Yaqoob
The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease
QJM, April 1, 2009; 102(4): 261 - 269.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
M. S Joy and G. R Matzke
Nephrology Pharmacy: Historical Reflections and Future Challenges
Ann. Pharmacother., November 1, 2007; 41(11): 1884 - 1886.
[Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. Tomlinson
How Do We Re-Design the Treatment?: A Background Paper prepared for the UK Consensus Conference on Early Chronic Kidney Disease
Nephrol. Dial. Transplant., September 1, 2007; 22(suppl_9): ix39 - ix44.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
N. Halbesma, D.-S. Kuiken, A. H. Brantsma, S. J.L. Bakker, J. F.M. Wetzels, D. De Zeeuw, P. E. De Jong, R. T. Gansevoort, and for the PREVEND Study Group
Macroalbuminuria Is a Better Risk Marker than Low Estimated GFR to Identify Individuals at Risk for Accelerated GFR Loss in Population Screening
J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2582 - 2590.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
S. Shah, J. Dowell, and S. Greene
Evaluation of Clinical Pharmacy Services in a Hematology/Oncology Outpatient Setting
Ann. Pharmacother., September 1, 2006; 40(9): 1527 - 1532.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2005 by Harvey Whitney Books Company.